Patrick M Sweeney & Associates Inc. Has $2.64 Million Position in Eli Lilly and Company (NYSE:LLY)

Patrick M Sweeney & Associates Inc. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,984 shares of the company’s stock after buying an additional 56 shares during the period. Eli Lilly and Company accounts for approximately 1.9% of Patrick M Sweeney & Associates Inc.’s portfolio, making the stock its 9th largest holding. Patrick M Sweeney & Associates Inc.’s holdings in Eli Lilly and Company were worth $2,644,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. M&G Plc bought a new position in shares of Eli Lilly and Company in the 1st quarter worth $8,896,000. Virtu Financial LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at about $2,138,000. China Universal Asset Management Co. Ltd. raised its position in Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares in the last quarter. Mutual Advisors LLC lifted its stake in Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after purchasing an additional 50,197 shares during the last quarter. Finally, Private Advisor Group LLC boosted its holdings in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after purchasing an additional 430 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LLY. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $891.66 on Friday. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53. The stock’s 50 day simple moving average is $921.12 and its two-hundred day simple moving average is $860.74. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a market cap of $847.44 billion, a price-to-earnings ratio of 131.32, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.